the Quality of Life Assessment of Lung Cancer Patients in China

A Multicenter, Observational, Phase III Clinical Study: the Quality of Life Assessment of Lung Cancer Patients in China.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01914120

Enrollment

3000

Registered

2013-08-01

Start date

2012-11-30

Completion date

2017-06-30

Last updated

2015-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

lung cancer, quality of life, FACT-L

Brief summary

The goal of this study is assess the quality of life of advanced non-small cell lung cancer (NSCLC) patients who are undergoing first-line chemotherapy, analyze the current status and tendency of quality of life (QOL). The method is to use the Functional Assessment of Cancer Therapy-Lung (FACT-L) scales, assess the quality of life before the chemotherapy, after 1st cycle of chemotherapy and after 2nd cycle. After 3 time-points, investigators analyze all the subscales and constructs of FACT-L. The assumption is the quality of life will be better after 2 cycle of chemotherapy.

Detailed description

1. Lung cancer is the most deadly cancer in the world, 85% lung cancer are non-small cell lung cancer (NSCLC). The quality of life of NSCLC patients become more and more important, because of most NSCLC is incurable. 2. The recruitment will take place in 20 center all over the country and 500 patients will enrolled.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* age: \>18 and \<75 years old * pathological or cytological diagnosis confirmed advanced non-small cell lung cancer * Eastern Cooperative Oncology Group Performance Status: 0-2 * have never receive any kind of anti-cancer chemotherapy * agree to regularly assessment of quality of life * sign the informed consent form

Exclusion criteria

* Currently attending any antitumor drug clinical trials * Pregnancy or breast-feeding women * Currently receiving anti-tumor chemotherapy, or received any antitumor chemotherapy previously. * not suitable to participate in this test

Design outcomes

Primary

Measure	Time frame	Description
the change of quality of life	Change from baseline quality of life at 6 weeks	use Functional Assessment of Cancer Therapy-Lung (FACT-L) scales assess the quality of life to all subjects. before chemotherapy; after 1st chemotherapy; after 2nd chemotherapy;

Secondary

Measure	Time frame
overall survival	24 months

Countries

China

Contacts

Primary ContactYuXiang Ma

mayx@sysucc.org.cn86-020-87343786

Outcome results